Biogen Inc (NASDAQ:BIIB)
| 252.86 Delayed Data As of Oct 02 |  -4.15 / -1.61%Today’s Change | 250.31 Today|||52-Week Range 319.76 | -8.69% Year-to-Date |
Latest BIIB News | Press Releases
| Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know Oct 02 / Zacks.com - Paid Partner Content | Novartis' (NVS) Sandoz Gets EC Nod for Tysabri's Biosimilar Sep 26 / Zacks.com - Paid Partner Content |
| Is Biogen Stock a Buy Now? Sep 28 / MotleyFool.com - Paid Partner Content | Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know Sep 25 / Zacks.com - Paid Partner Content |
| Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs Sep 28 / Zacks.com - Paid Partner Content | Unveiling Biogen (BIIB)'s Value: Is It Really Priced Right? A Comprehensive Guide Sep 25 / GuruFocus News - Paid Partner Content |
| Intercept Pharmaceuticals (ICPT) Surges on Acquisition Deal Sep 27 / Zacks.com - Paid Partner Content | Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know Sep 18 / Zacks.com - Paid Partner Content |
| Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5% Sep 27 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 257.01 |
| Today’s open | 256.29 |
| Day’s range | 251.19 - 256.29 |
| Volume | 33,457 |
| Average volume (3 months) | 1,041,733 |
| Market cap | $37.2B |
Data as of 4:00pm ET, 10/02/2023
Growth & Valuation
| Earnings growth (last year) | +100.92% |
| Earnings growth (this year) | -12.67% |
| Earnings growth (next 5 years) | +4.11% |
| Revenue growth (last year) | -9.32% |
| P/E ratio | 13.8 |
| Price/Sales | 4.29 |
| Price/Book | 2.76 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MRNAModerna Inc | +0.01 | +0.01% |
| ILMNIllumina Inc | -0.84 | -0.61% |
| ---- | ||
| BMRNBiomarin Pharmaceuti... | -1.41 | -1.59% |
Data as of 4:00pm ET, 10/02/2023
Financials
| Next reporting date | October 24, 2023 |
| EPS forecast (this quarter) | $4.07 |
| Annual revenue (last year) | $9.4B |
| Annual profit (last year) | $3.0B |
| Net profit margin | 32.30% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
